Beacon launches new drug Ribotix in global market

Ribotix is a CDK4/6 inhibitor that is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

Ribociclib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of Cancer cells.

The company launched Ribotix (Ribociclib 200mg) tablet for the global market. It will be available in a single strength of 200 mg. Each pack of Ribotix will contain 63 Tablets.

The company wishes for the success of the product in the global market hoping that it will garner a global image for the company and will increase its export sales.